Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Experimental RNAi02:15

Experimental RNAi

8.0K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
8.0K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

19.8K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
19.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic and therapeutic significance of RKIP and YY1 in cancer, autoimmune disorders, and inflammatory pathologies.

Biochimica et biophysica acta. Reviews on cancer·2026
Same author

Research Article: The Dysregulated YY1-Bcl-2-c-Myc Axis in Non-Hodgkin Lymphoma: Validation by Bioinformatic Analyses.

Critical reviews in oncogenesis·2026
Same author

Review Article: EZH2 in Pancreatic Cancer: Epigenetic Driver and Therapeutic Target.

Critical reviews in oncogenesis·2026
Same author

TGF-β-YY1 signaling as a key driver of immune evasion in pancreatic cancer: Therapeutic implications.

Cytokine & growth factor reviews·2026
Same author

The implied dysregulated RKIP-hypoxia axis in cancer and immune evasion: Clinical implications.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2025
Same author

The YYR (YY1- RKIP) Regulatory Axis in the pathogenesis of Cancer and Immune Evasion.

Journal of experimental & clinical cancer research : CR·2025

Related Experiment Video

Updated: Feb 27, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K

The Role of Raf Kinase Inhibitor Protein (RKIP) in HER2+ Breast Cancer Immune Evasion.

Ania Khachikian1, Mai Ho1, Benjamin Bonavida1

  • 1Department of Microbiology, Immunology & Molecular Genetics, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095, USA.

Cells
|February 26, 2026
PubMed
Summary

HER2+ breast cancer (BC) involves immune evasion. Underexpression of Raf Kinase Inhibitor Protein (RKIP) worsens this. Targeting the RKIP-HER2 axis may overcome treatment resistance in HER2+ BC.

Keywords:
HER2RKIPbreast cancercross-talk signalingimmune evasionimmunotherapytargeting

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Experiment Videos

Last Updated: Feb 27, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.6K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • HER2 overexpression drives breast cancer (BC) and immune evasion.
  • Raf Kinase Inhibitor Protein (RKIP) suppresses metastasis and enhances immunity but is underexpressed in HER2+ BC.
  • Current anti-HER2 therapies show limited efficacy due to resistance, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To investigate the relationship between RKIP and HER2 signaling in HER2+ BC.
  • To elucidate the role of the RKIP-HER2 axis in immune evasion within the tumor microenvironment (TME).
  • To identify therapeutic strategies targeting the RKIP-HER2 axis to overcome treatment resistance and immune evasion.

Main Methods:

  • Analysis of signaling pathways mediated by RKIP and HER2 in HER2+ BC.
  • Bioinformatic analyses to corroborate findings on the RKIP-HER2 axis.
  • Evaluation of RKIP and HER2 roles in regulating immune cell infiltration and function within the TME.

Main Results:

  • An inverse relationship was observed between RKIP and HER2 downstream signaling, indicating a dysregulated RKIP-HER2 axis in HER2+ BC.
  • HER2 overexpression promotes immune evasion by upregulating PD-L1, polarizing TAMs, increasing suppressor cells (Tregs, MDSCs), and inhibiting CD8+ T cells.
  • RKIP expression was found to inhibit key signaling pathways (Raf-MEK-ERK, NF-kB, PI3K/Akt), thereby counteracting HER2-mediated immune evasion mechanisms.

Conclusions:

  • A novel dysregulated RKIP-HER2 axis in HER2+ BC contributes to immune evasion and therapeutic unresponsiveness.
  • Targeting the RKIP-HER2 axis presents a promising therapeutic strategy to enhance treatment efficacy and overcome immune evasion in HER2+ BC.
  • Understanding the cross-talk between RKIP and HER2 is crucial for developing effective treatments for HER2+ breast cancer.